Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Jack L. Wyszomierski sold 8,768 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Exelixis Stock Up 2.8 %
Shares of NASDAQ EXEL opened at $38.69 on Friday. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $38.72. The business has a 50 day moving average price of $34.53 and a two-hundred day moving average price of $31.62. The firm has a market cap of $10.83 billion, a PE ratio of 21.86, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53.
Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the 4th quarter worth approximately $25,000. Colonial Trust Co SC grew its position in shares of Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares in the last quarter. USA Financial Formulas acquired a new position in shares of Exelixis in the 4th quarter worth approximately $32,000. Principal Securities Inc. grew its position in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Finally, Kestra Investment Management LLC acquired a new position in shares of Exelixis in the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 85.27% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. Bank of America lowered Exelixis from a "buy" rating to a "neutral" rating and raised their price target for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. Guggenheim restated a "buy" rating and issued a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. StockNews.com upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 19th. JMP Securities restated a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Finally, Stephens restated an "equal weight" rating and issued a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.24.
View Our Latest Stock Analysis on Exelixis
About Exelixis
(
Get Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
